Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Finished Goods (2023 - 2026)

Catalyst Pharmaceuticals filings provide 4 years of Finished Goods readings, the most recent being $15.3 million for Q1 2026.

  • On a quarterly basis, Finished Goods rose 88.21% to $15.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.3 million, a 88.21% increase, with the full-year FY2025 number at $16.2 million, up 68.7% from a year prior.
  • Finished Goods hit $15.3 million in Q1 2026 for Catalyst Pharmaceuticals, down from $16.2 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $16.2 million in Q4 2025 to a low of $8.1 million in Q1 2025.
  • Median Finished Goods over the past 4 years was $9.2 million (2024), compared with a mean of $10.6 million.
  • Biggest five-year swings in Finished Goods: decreased 3.29% in 2025 and later soared 88.21% in 2026.
  • Catalyst Pharmaceuticals' Finished Goods stood at $9.2 million in 2023, then rose by 4.55% to $9.6 million in 2024, then surged by 68.7% to $16.2 million in 2025, then decreased by 5.43% to $15.3 million in 2026.
  • The last three reported values for Finished Goods were $15.3 million (Q1 2026), $16.2 million (Q4 2025), and $11.3 million (Q3 2025) per Business Quant data.